Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 8/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.40 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | KIT | P10721 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12876620 | 0.92 | CACNA1H (0.47) | CACNA1HCYP3A4TRPV1ROCK2PRKG1 | |
| SCHEMBL12877049 | 0.89 | CACNA1H (0.53) | CACNA1HCYP3A4TRPV1ROCK2PRKG1 | |
| SCHEMBL8213093 | 0.89 | CACNA1H (0.53) | CACNA1HCYP3A4TRPV1ROCK2PRKG1 | |
| SCHEMBL12877046 | 0.87 | CACNA1H (0.62) | CACNA1HCYP3A4TRPV1 | |
| SCHEMBL12876968 | 0.84 | CACNA1H (0.75) | CACNA1HTRPV1 | |
| SCHEMBL12877006 | 0.84 | CACNA1H (0.72) | CACNA1HKIT | |
| SCHEMBL12876956 | 0.84 | CACNA1H (0.53) | CACNA1HTRPV1KITCNR2 | |
| SCHEMBL8224856 | 0.81 | CACNA1H (0.47) | CACNA1HCYP3A4ROCK2PRKG1KIT | |
| SCHEMBL8224566 | 0.81 | CACNA1H (0.47) | CACNA1HCYP3A4ROCK2PRKG1KIT | |
| SCHEMBL8225683 | 0.80 | CACNA1H (0.47) | CACNA1HCYP3A4TRPV1KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884080-B2 | Administering an azetidinone compound for treating a disorder of lipid metabolism, pain, diabetes, a vascular condition, demyelination or nonalcoholic fatty liver disease; T-type calcium channel blocking agent, an antagonist of TRPV1, an agonist of TRPV1, of GPR119, antagonist of NPCL1 | SCHERING PLOUGH CORPORATION (US) | 2011-02-08 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | MERCK SHARP & DOHME CORP. | 2008-03-27 | — | — | US | disclosed |
| WO-2008033464-A2 | AZETIDINONE DERIVATIVES FOR THE TREATMENT OF DISORDERS OF THE LIPID METABOLISM | SCHERING CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076751-A1 | Azetidinone Derivatives and Methods of Use Thereof | LIPC, ZDHHC20, FABP1 | CACNA1H 2929/4885CYP3A4 343/4885TRPV1 771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.